**State Medicaid Alternative Reimbursement and Purchasing Test for High-cost Drugs** [SMART-D] Project **Prescription Drug Alternative Payment Models and Medicaid** 

Washington Prescription Drug Price and Purchasing Summit Series – Part 2 September 22, 2016

> Jane Beyer, Program Officer Milbank Memorial Fund/OHSU Center for Evidence-based Policy

> > 60710

# **Today's Objective**

- Understand:
  - The federal Medicaid Drug Rebate Program\*
  - Alternative payment model (APM) opportunities and risks for state Medicaid programs under current federal law

\* Section 1927 of the Social Security Act



# **SMART-D Project Goals**


The Center for Evidence-based Policy (CEbP) at Oregon Health & Science University has undertaken a three-year, three-phase pilot program funded by the Laura and John Arnold Foundation. The program has the following purposes:

- to strengthen the ability of Medicaid programs to manage prescription drugs through alternative payment methodologies, and
- to provide Medicaid leaders with opportunities to shape the national conversation on prescription drug innovation, access, and affordability


50710

3

### **Summary of Project Phases**



# Prescription drug APM's are designed in a broader context



#### Medicaid Prescription Drug APM's – Putting the Pieces Together



# Legal and Compliance Analysis Framework

Bill von Oehsen and his team at Powers Pyles Sutter & Verville PC developed a detailed legal analysis for:

- Understanding the current federal and state legal framework for Medicaid prescription drug coverage and payment through the Medicaid Drug Rebate Program (MDRP).
- Exploring potential options within and outside MDRP to use APMs to drive the use of clinically valuable drugs and manage prescription drug costs.



# Legal and Compliance Analysis Framework

- Accommodate different state Medicaid delivery system models (fee-for-service or managed care contracting).
- Support value-based payment approaches with pharmacies and other health care providers, in addition to agreements negotiated directly with prescription drug manufacturers.
- Align with state Medicaid value-based payment and delivery system transformation efforts.



### APMs and value-based purchasing are not always the same

- Alternative payment models: a contract between a payer and drug manufacturer that ties payment to an agreed-upon measure
  - financial-based
  - health outcomes-based
- Value-based purchasing: a payer contract or other arrangement with either a drug manufacturer or provider/pharmacy that ties payment to evidencebased standards of clinical care
  - manufacturer contract
  - managed care organizations (MCOs), provider networks, health care providers



# **Federal and State Requirements**

- Medicaid Drug Rebate Program (MDRP)
  - Rebate calculation is statutorily fixed
  - Rebates are NDC-specific, not indication-specific
  - States cannot use closed formularies, although preferred drug lists are allowed
  - Prescription limits are regulated
- Medicaid Non-MDRP
  - Fee-for-service reimbursement for retail drugs is set at actual acquisition cost
  - Patient cost-sharing is subject to limits



# Federal and State Requirements (cont'd)

- Other federal issues
  - Prohibition against off-label promotion by manufacturers
  - Anti-kickback statute
  - Overlapping discounts with 340B prices, payer rebates, etc.
- Relevant state law
  - Preferred drug list and prior authorization exclusions
  - "Any willing provider" laws
  - Regulation of MCOs and pharmacy benefit managers
    (PBMs) requiring transparency, etc.

101700

### **State Opportunities Pathway One: Supplemental Rebate Arrangements**

Use of preferred drug lists, prior authorization, or other tools to negotiate supplemental rebates linked to financial- or outcomebased APMs with manufacturers for fee-for-service drugs

### **Opportunities**

- Rebates can be adjustable/indication specific
- Supplemental rebates are exempt from "best price" determinations
- Infrastructure already in place
- Multistate rebates permitted •
- Accepted and supported by Centers for Medicare & Medicaid Services (CMS) • https://www.medicaid.gov/Medicaid-CHIP-Program-Information/ By-Topics/Benefits/Prescription-Drugs/Downloads/Rx-Releases/ State-Releases/state-rel-176.pdf



### State Opportunities Pathway One: Supplemental Rebate Arrangements

#### <u>Risks</u>

- Indication-specific rebates could be difficult to negotiate because MDRP rebates are NDC-specific
- Preferred drug list is weaker than closed formulary
- Still subject to Medicaid prescription limits and patient costsharing restrictions



## State Opportunities Pathway Two: MCO Contracting

State outsources to MCOs the task of negotiating supplemental rebates. MCO's have flexibility on drug ingredient and dispensing-fee payment methodologies

### **Opportunities**

- Same as Pathway One
- Takes advantage of MCO/PBM rebate negotiation experience
- Can be used in conjunction with Pathway One to cover fee-for-service and MCO settings
- Can be coupled with provider value-based purchasing initiatives for retail drugs and physician-administered drugs (PAD)



# State Opportunities Pathway Two: MCO Contracting

#### <u>Risks</u>

- Could conflict with existing MCO/PBM rebate arrangements. Would need to address through MCO contracting.
- Uncertain as to whether MCOs can negotiate supplemental rebates "on behalf of" the state and thus retain "best price" determination exemption.
- Still subject to Medicaid prescription limits and patient cost-sharing restrictions.
- Potential role of state regulation of MCOs/PBMs or preferred drug lists.
- More significant off-label promotion and anti-kickback statute risks.



## State Opportunities Pathway Three: MCO/340B Covered Entity Partnerships

Value-based purchasing arrangements with 340B providers/pharmacies for 340B drugs reimbursed by state's MCOs, with or without accompanying APM arrangement with manufacturer

### **Opportunities**

- Rebates can be adjustable/indication specific
- 340b drug prices are exempt from "best price" determination
- 340B price is below Medicaid net price, so less pressure to negotiate large rebates if covered entities share savings with MCOs
- Can establish closed formulary
- Exempt from MDRP prescription limits
- Can establish "centers of excellence" and "whole person"
- 15 care models with covered entities



# State Opportunities Pathway Three: MCO/340B Covered Entity Partnerships

### <u>Risks</u>

- Need cooperation of 340B covered entities
- Need utilization, patient outcome, and other data from covered entities
- Need to establish this arrangement through MCO contracting
- More significant off-label promotion and anti-kickback statute risks
- Potential role of state "any willing provider" and PBM/MCO laws



### State Opportunities Pathway Four: Hospital-Dispensed Covered Outpatient Drugs

Enter into manufacturer APM rebate and provider value-based purchasing arrangements for covered outpatient drugs dispensed by hospitals and billed at no more than their purchasing costs

#### **Opportunities**

- Adjustable/indication-specific rebates permitted
- Closed formulary allowed
- Exempt from MDRP prescription limits
- Allows establishing "centers of excellence" and "whole person" care models with hospitals
- Less pressure to negotiate large rebates because 340B and non-340B hospitals bill at no more than their "purchasing costs"
- States can define "purchasing costs" in their state plan
- Can be used in conjunction with Pathway Three with 340b hospitals



## State Opportunities Pathway Four: Hospital-Dispensed Covered Outpatient Drugs

#### <u>Risks</u>

- Need cooperation of hospitals to bill at no more than their "purchasing costs"
- Need utilization, patient outcome, and other data from hospitals
- Unclear whether rebates or pricing negotiated by non-340b hospitals would qualify for "best price" exemption
- No flexibility on actual acquisition cost reimbursement for retail drugs
- No guidance from CMS on how to comply with applicable federal law



### State Opportunities Pathway Five: PADs That Fall Outside "Covered Outpatient Drug" Definition

Enter into manufacturer APM rebate and provider value-based purchasing arrangements for PADs that fall outside "covered outpatient drug" definition

#### **Opportunities**

- Adjustable/indication-specific rebates permitted
- Closed formulary allowed
- Exempt from MDRP prescription limits
- Allows establishing provider payment models built around specific disease states or episodes of care that involve the administration of high-cost drugs
- Provider payments would not be subject to actual acquisition cost reimbursement and could be structured to create incentives for favorable patient outcomes



### State Opportunities Pathway Five: PADs That Fall Outside "Covered Outpatient Drug" Definition

### <u>Risks</u>

- State would have to be willing to surrender MDRP rebates, which may be difficult to make up
- No clear exemption from "best price" determination
- Unclear how model would work in managed care environment
- Need utilization, patient outcome, and other data from providers
- Model is untested



## State Opportunities Pathway Six: Alternative Benefit Plan

Pathway Six: Section 1937 Alternative Benefit Plans

Establish closed formulary for drugs provided to Medicaid expansion populations that receive essential health benefits under Affordable Care Act

### **Opportunities**

 Closed formulary to focus on most clinically effective and costeffective drugs



### State Opportunities Pathway Six: Alternative Benefit Plan

#### <u>Risks</u>

- For states that have not implemented an alternative benefit plan, complexity of administering a separate benefit package.
- Complexity of administering option for medically frail enrollees to receive benefits through the traditional Medicaid benefit package.



## State Opportunities Pathway Seven: Section 1115 Waiver

Seek to relax formulary restrictions and other MDRP requirements in order to test new value-based purchasing models for prescription drugs and related services

### **Opportunities:**

- Align prescription drugs with states' broader value-based purchasing initiatives, via waiver of MDRP limitations
- Build prescription drugs into ACO-like payment models or directives to MCOs to increase use of alternative payment models, allowing flexibility for drug utilization and cost management by ACOs and MCOs



### State Opportunities Pathway Seven: Section 1115 Waiver

### <u>Risks:</u>

- 1115 waiver or waiver amendment must be approved by CMS through an extensive process
- Federal budget neutrality requirement must be met



# **Anti-Kickback Statute**

- The Anti-Kickback Statute is a criminal statute that prohibits intentional exchange of, or offer to exchange, anything of value to induce or reward the referral of federal health care program business.
- 10 types of arrangements excluded from criminal liability in statute, plus HHS/OIG defined "safe harbors." Currently, there are 25 safe harbors.
- Most relevant are discounts or reductions in price, which include rebates and risk sharing between MCOs and their first-tier contractors.



# **Anti-Kickback Statute**

- If exclusion or safe harbor does not apply, then HHS evaluates on case-by-case basis.
  - OIG instruction to manufacturers: In assessing whether an arrangement might create undue risk, consider the potential to:
    - affect clinical decision making,
    - increase costs to federal health care programs,
    - increase risk of overutilization or inappropriate utilization,
    - create safety or quality of care concerns
- To date, HHS has not issued any regulatory guidance or advisory opinions on APM arrangements. Thus, there's no certainty as to how the OIG would view a particular APM established within a state Medicaid program.



# **Anti-Kickback Statute**

- Two factors likely reduce the risk that the OIG would consider any Medicaid APM as violating the Anti-Kickback Statute:
  - 1. Manufacturer negotiates directly with a state rather than a commercial entity
  - 2. Arrangement is reviewed and approved by CMS



# **Off-Label Promotion**

- Off-label promotion is a form of "misbranding," treated as a criminal violation under the Food, Drug, and Cosmetic Act. When off-label drugs are billed to Medicaid, the manufacturer can face False Claims Act prosecution.
- Questions:
  - Does a health outcome-based APM involve potential offlabel use of a drug?
  - If so, could it violate federal law?



# **Off-Label Promotion**

- Measures to limit risk if off-label use is involved:
  - Manufacturer truthfulness, so there is no question of influencing a state's decision about payment associated with the APM.
  - Reliance upon independent clinical data, rather then manufacturer's assertion.
  - Obtaining CMS review and approval.
- Truthful discussions of off-label uses between a drug manufacturer and a state Medicaid agency might be constitutionally protected, based upon recent litigation.



### Phase Two: August 2016 to April 2017

Implementation Plan for Alternative Purchasing Models Develop Alternative Purchasing Models

APM Readiness Assessment Tool

Business Case/ Analytical Framework

Legal Tools for States

Selection of Phase 3 Implementation States

## **Resources & Contact Information**

SMART-D website: www.smart-d.org

Jane Beyer, Program Officer MMF/CEbP Direct Dial: 503-418-2065 E-mail: <u>beyerj@ohsu.edu</u>

**Bill von Oehsen,** Principal Powers Pyles Sutter & Verville PC Direct Dial: (202) 872-6765 E-mail: <u>william.vonoehsen@ppsv.com</u>



### Appendix: Laura and John Arnold Foundation Prescription Drug Portfolio Strategy

Other grantees in the portfolio strategy:

- Initiative for Medicines, Access, and Knowledge
- Harvard Medical School
- Memorial Sloan Kettering Cancer Institute
- Johns Hopkins/Bloomberg School of Public Health
- Institute of Medicine
- Institute for Clinical and Economic Review
- Kaiser Health News

